18F-FDG PET/CT in lung B lymphoid hyperplasia-type Castleman disease

  • Paula Fernández-RodríguezEmail author
  • Rosa Fernández López
  • Irene Acevedo Báñez
  • Javier Mohigefer Barrera
  • José Manuel Jiménez-Hoyuela García
Image of the Month
Part of the following topical collections:
  1. Image of the month


We present a 62-year-old woman who, after a catarrhal episode, underwent a chest xray and a chest CT, identifying a pleural-based mass in the left lower lobe. This lesion presented a mixed pattern with solid and peripheral ground-glass attenuation, and an air-bronchogram sign. Despite de suspicion of bronchopneumonia, a lung neoplasm like a predominantly lepidic adenocarcinoma could not be ruled. A 18 F-FDG PET/CT showed a focal radiotracer uptake with SUVmax of 5.34 in the pulmonary lesion, supporting the neoplastic etiology. Consequently, a lower lobectomy was performed and histological examination concluded that the final diagnosis was a B lymphoid hyperplasia-type Castleman disease. Castleman’s disease is an uncommon disorder that can be easily misdiagnosed as lymphoma, neoplasm or infection. Unicentric Castleman’s disease (UCD) usually presents a hyaline-vascular histological subtype and is usually asymptomatic. Extranodal involvement is very rare. Only a few cases of solid organ involvement such us spleen or parotid gland have been described. UCD originating in the lung is extremely rare and should be considered in the differential diagnosis of a primary pulmonary malignant tumor.


Pulmonary mass 18F-FDG PET/CT Unicentric Castleman Disease Hyaline-sclerosing transformation 


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Informed consent

Written informed consent was obtained from the patient for the anonymous use of patient clinical, imaging, and histologic data. All procedures performed in this study involving human participants were in accordance with the ethical standards of the local Ethics and Research Hospital Committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.


  1. 1.
    Mantas D, Damaskos C, Dailiani P, Samarkos M, Korkolopoulou P. Castleman’s disease of the spleen. Acta Chir Belg. 2017;117:203–8.CrossRefGoogle Scholar
  2. 2.
    Rawashdeh B, Meyer M, Yimin D, Anthony C, Nguyn D, Moslemi M, et al. Unicentric Castleman’s disease presenting as a pulmonary mass: a diagnostic dilemma. Am J Case Rep. 2015;16:259–61.CrossRefGoogle Scholar
  3. 3.
    Wong RSM. Unicentric Castleman disease. Hematol Oncol Clin North Am. 2018;32:65–73.CrossRefGoogle Scholar
  4. 4.
    Temirbekov D, Yazici ZM, Ergelen R, Turgut H, Kayhan FT. Castelman disease of the parotid gland: an unusual entity. Otolaryngol Pol. 2014;68:208–11.CrossRefGoogle Scholar
  5. 5.
    Liu Y, Chen G, Qiu X, Xu S, Wu Y, Liu R, et al. Intrapulmonary unicentric Castleman disease mimicking peripheral pulmonary malignancy. Thorac Cancer. 2014;5:576–80.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Nuclear MedicineVirgen del Rocío University HospitalSevilleSpain
  2. 2.Department of PathologyVirgen del Rocío University HospitalSevilleSpain

Personalised recommendations